Oragenics (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics via proprietary intranasal delivery technology, announced it has regained full compliance with NYSE American’s continued listing standards. Effective Oct. 20, 2025, the exchange confirmed compliance with Section 1003(a)(iii), removing the below-compliance indicator and restoring the company to the roster of compliant issuers. “Regaining compliance represents more than a regulatory milestone—it reflects our commitment to transparency, financial discipline, and restoring investor confidence,” said CEO Janet Huffman. The achievement follows the July 2, 2025, closing of a $16.5 million public offering of Series H Convertible Preferred Stock, which restored stockholder equity and funds advancement of ONP-002 through key Phase II milestones in Australia and upcoming Phase IIb trials in the U.S.

To view the full press release, visit https://ibn.fm/bd7Im

About Oragenics Inc.

Oragenics is striving to revolutionize neurological care through proprietary intranasal delivery technology that has the potential to enable targeted, non-invasive therapeutics for brain-related conditions. Our lead candidate, ONP-002, is advancing with the goal of becoming the first FDA-approved treatment for concussion, while our platform technology has the potential, we believe, to open pathways to address neurodegenerative diseases, CNS disorders, and other neurological conditions.

We’re building more than a pharmaceutical company—we’re creating a movement around brain-first recovery that transforms how patients, clinicians, and healthcare systems approach neurological trauma.

NOTE TO INVESTORS: The latest news and updates relating to OGEN are available in the company’s newsroom at https://ibn.fm/OGEN

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN